CompletedPhase 4

Lung Lavage With Dilute Poractant Alfa for Meconium Aspiration Syndrome

Turkey (Türkiye)30 participantsStarted 2013-09

Plain-language summary

Meconium aspiration syndrome (MAS) is an important cause of severe respiratory failure in newborn infants. Treatment for MAS is mainly supportive but surfactant therapy might change the course of the disease. Aim of the study to evaluate whether lung lavage with dilute or bolus poractant alfa changes the duration of mechanical respiratory support or other outcomes in MAS.

Who can participate

Age range7 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Infants with a gestational age ≥ 36 weeks, birth weight ≥ 2.0 kg, evidence of passage of meconium at or before delivery, typical chest radiology findings and mechanically ventilated infants with a mean airway pressure ≥ 12 cm H2O were enrolled. Exclusion Criteria: * Congenital cardiac anomalies * Major congenital anomalies * Hemodynamically unstable infants

What they're measuring

Duration of mechanical ventilation

Timeframe: up to 2 weeks

Trial details

NCT IDNCT02041546

SponsorZekai Tahir Burak Women's Health Research and Education Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-12

View on ClinicalTrials.gov More Meconium Aspiration Syndrome trials